TrialJournal for immunotherapy of cancer2025

Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020.

Paolo A Ascierto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.